Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2008-04-15
2008-04-15
Qian, Celine (Department: 1636)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C514S002600
Reexamination Certificate
active
07358330
ABSTRACT:
The invention relates to compounds exhibiting immunoregulatory activity as determined by measuring the compound's ability to modulate production of NO by a cell. Preferred compounds include or consist of a sequencein-line-formulae description="In-line Formulae" end="lead"?AAL AAQ AAG AAVin-line-formulae description="In-line Formulae" end="tail"?wherein AAL is a substituted or unsubstituted non-polar amino acid selected from the group consisting of Ala and Leu; wherein AAQ is a substituted or unsubstituted amino acid selected from the group consisting of Gln, Pro, and Ala; wherein AAG is a substituted or unsubstituted amino acid Gly, and wherein AAV is a substituted or unsubstituted non-polar amino acid selected from the group consisting of Val and Ala. In one embodiment, the compound consists of a tripeptide selected from the group AQG, MTR, VVC, and mixtures thereof.
REFERENCES:
patent: 4427660 (1984-01-01), Schiffman et al.
patent: 4571336 (1986-02-01), Houck et al.
patent: 4753965 (1988-06-01), Stemerick et al.
patent: 4855285 (1989-08-01), Stevens
patent: 4977244 (1990-12-01), Muchmore et al.
patent: 5002961 (1991-03-01), Dage et al.
patent: 5223397 (1993-06-01), Pouletty
patent: 5380668 (1995-01-01), Herron
patent: 5677275 (1997-10-01), Lunardi-Iskandar et al.
patent: 5801193 (1998-09-01), Ojo-Amaize et al.
patent: 5837478 (1998-11-01), Gallatin et al.
patent: 5851997 (1998-12-01), Harris
patent: 5854004 (1998-12-01), Czemilofsky et al.
patent: 5856440 (1999-01-01), Wang
patent: 5877148 (1999-03-01), Lunardi-Iskandar et al.
patent: 5942494 (1999-08-01), Ginsberg et al.
patent: 5958413 (1999-09-01), Anagnostopulos et al.
patent: 5968513 (1999-10-01), Gallo et al.
patent: 5972924 (1999-10-01), Keep et al.
patent: 5981486 (1999-11-01), Matsushima et al.
patent: 5994126 (1999-11-01), Steinman et al.
patent: 5997871 (1999-12-01), Gallo et al.
patent: 6051596 (2000-04-01), Badger
patent: 6075150 (2000-06-01), Wang et al.
patent: 6150500 (2000-11-01), Salerno
patent: 6235281 (2001-05-01), Stenzel et al.
patent: 6310041 (2001-10-01), Haddox et al.
patent: 6319504 (2001-11-01), Gallo et al.
patent: 6361992 (2002-03-01), Szkudlinski et al.
patent: 6489296 (2002-12-01), Grinnell et al.
patent: 6583109 (2003-06-01), Gallo et al.
patent: 6596688 (2003-07-01), Gallo et al.
patent: 6620416 (2003-09-01), Gallo et al.
patent: 6630138 (2003-10-01), Gerlitz et al.
patent: 6727227 (2004-04-01), Khavinson
patent: 6831057 (2004-12-01), Baldwin et al.
patent: 6844315 (2005-01-01), Khan et al.
patent: 2002/0041871 (2002-04-01), Brudnak
patent: 2002/0064501 (2002-05-01), Khan et al.
patent: 2003/0049273 (2003-03-01), Gallo et al.
patent: 2003/0113733 (2003-06-01), Khan et al.
patent: 2003/0119720 (2003-06-01), Khan et al.
patent: 2003/0148955 (2003-08-01), Pluenneke
patent: 2003/0166556 (2003-09-01), Khan et al.
patent: 2003/0186244 (2003-10-01), Margus et al.
patent: 2003/0215434 (2003-11-01), Khan et al.
patent: 2003/0219425 (2003-11-01), Khan et al.
patent: 2003/0220257 (2003-11-01), Benner et al.
patent: 2003/0220258 (2003-11-01), Benner et al.
patent: 2003/0220259 (2003-11-01), Benner et al.
patent: 2003/0220260 (2003-11-01), Khan et al.
patent: 2003/0220261 (2003-11-01), Khan et al.
patent: 2003/0224995 (2003-12-01), Khan et al.
patent: 2004/0013661 (2004-01-01), Wensvoort et al.
patent: 2005/0037430 (2005-02-01), Khan et al.
patent: 2005/0214943 (2005-09-01), Khan et al.
patent: 2005/0227925 (2005-10-01), Benner et al.
patent: 2006/0111292 (2006-05-01), Khan et al.
patent: 2006/0142205 (2006-06-01), Benner et al.
patent: 3715662 (1987-11-01), None
patent: 19953339 (2001-05-01), None
patent: 1 138 692 (2001-10-01), None
patent: 1 300 418 (2003-04-01), None
patent: 2 706 772 (1994-12-01), None
patent: 2 194 886 (1988-03-01), None
patent: WO 96/04008 (1996-02-01), None
patent: WO 97/49373 (1997-12-01), None
patent: WO 97/49418 (1997-12-01), None
patent: WO 97/49432 (1997-12-01), None
patent: WO 97/49721 (1997-12-01), None
patent: WO 98/34631 (1998-08-01), None
patent: WO 98/35691 (1998-08-01), None
patent: WO 99/59617 (1999-11-01), None
patent: WO 01/10907 (2001-02-01), None
patent: WO 01/11048 (2001-02-01), None
patent: WO 01/29067 (2001-04-01), None
patent: WO 01/68113 (2001-09-01), None
patent: WO 01/72831 (2001-10-01), None
patent: WO 01/83554 (2001-11-01), None
patent: WO 02/085117 (2002-10-01), None
patent: WO 03/029292 (2003-04-01), None
PCT International Search Report, PCT/NL01/00259, dated Dec. 18, 2001, 3 pages.
PCT International Preliminary Examination Report, PCT/NL99/00313, dated Jul. 21, 2000, 6 pages.
PCT International Search Report, PCT/EP99/00313, dated Nov. 29, 1999, 3 pages.
International Search Report, International Application No. PCT/NL02/00639, mailed Aug. 4, 2003 (8 pages).
Connelly et al., Biphasic Regulation of NF-kB Activity Underlies the Pro- and Anti-Inflammatory Actions of Nitric Oxide, The Journal of Immunology, 2001, pp. 3873-3881, 166, The American Association of Immunologists, USA.
Friedlander, Tackling anthrax, Nature, Nov. 8, 2001, pp. 160-161, vol. 414.
Medzhitov, Toll-like Receptors and Innate Immunity, Nature Reviews/Immunology, Nov. 2001, pp. 135-145, vol. 1.
Lang et al., “Induction of apoptosis in Kaposi's sarcoma spindle cell cultures by the subunits of human chorionic gonadotropin”, AIDS 1997, vol. 11, No. 11, pp. 1333-1340.
Iskandar et al., “Effects of a urinary factor from women in early pregnancy on HIV-1. SIV and associated disease”, Nature Medicine, Apr. 1998, vol. 4, No. 4, pp. 428-434.
Christman et al., Nuclear factor kappaB: a pivotal role in the systemic inflammatory response syndrome and new target for therapy, Intens Care Med, 1998, pp. 1131-1138, vol. 24.
Jyonouchi et al., Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression, J Neuroim., 2001, pp. 170-179, vol. 120.
Kanungo et al., Advanced Maturation of Heteropneustes Fossilis (Bloch) by Oral Administration of Human Chorionic Gonadotropin, J. Adv. Zool., 1999, pp. 1-5, vol. 20.
Rohrig et al., Growth-stimulating Influence of Human Chorionic Gonadotropin (hCG) on Plasmodium falciparum in vitro, Zentralblatt Bakt, 1999, pp. 89-99, vol. 289.
Tak et al., NF-kappaB: a key role in inflammatory disease, J Clin Invest., 2001, pp. 7-11, vol. 107.
Tan et al., The role of activation of nuclear factor-kappa B of rat brain in the pathogenesis of experimental allergic encephalomyelitis, Acta Physiol Sinica, 2003, pp. 58-64, vol. 55.
Tovey et al., Mucosal Cytokine Therapy: Marked Antiviral and Antitumor Activity, J. Interferon Cytokine Res., 1999, pp. 911-921, vol. 19.
Albini, A., et al., “Old drugs as novel angiogenesis inhibitors: Preclinical studies with NAC, hCG, EGCG and somatostatin,” 17 Clinical & Experimental Metastasis 739 (1999).
Blackwell, Timothy S., et al., “The Role of Nuclear Factor-kB in Cytokine Gene Regulation,” 17 Am. J. Respir. Cell Mol. Biol. 3-9 (1997).
Keller, S., et al., “Human Chorionic Gonadotropin (hCG) Is a Potent Angiogenic Factor for Uterine Endothelial Cells in Vitro,” 20(5-6) PLACENTA, p. A37 (Jul. 1999).
Khan, Nisar A., et al., “Inhibition of Diabetes in NOD Mice by Human Pregnancy Factor,” 62(12) Human Immunology 1315-1323 (Dec. 2001).
Khan, Nisar A., et al., “Inhibition of Septic Shock in Mice by an Oligopeptide From the β-Chain of Human Chorionic Gonadotrophin Hormone,” 63(1) Human Immunology 1-7 (Jan. 2002).
Muchmore et al., Immunoregulatory Properties of Fractions from Human Pregnancy Urine: Evidence that Human Chorionic Gonadotropin is not Responsible, The Journal of Immunology, Mar. 1997, pp. 881-886, vol. 118, No. 3.
Muchmore et al., Purification and Characterization of a Mannose-Containing Disaccharide Obtained from Human Pregnancy Urine, Journal of Experimental Medicine, Dec. 1984, pp. 1672-1685, vol. 160.
Patil, A., et al., “The Study of the Effect of Human Chorionic Gonadotrophic (HCG) Hormone on the Survival of Adrenal Med
Benner Robbert
Khan Nisar Ahmed
Biotempt B.V.
Dunston Jennifer
Qian Celine
TraskBritt
LandOfFree
Immunoregulatory compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunoregulatory compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoregulatory compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2782605